WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The transaction is expected to close in Q2 FY 2026
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Subscribe To Our Newsletter & Stay Updated